ACM
PCRX icon

Atika Capital Management’s Pacira BioSciences PCRX Stock Holding History

Atika Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-31,000
Closed -$1.41M – 85
2017
Q1 		$1.41M Buy
+31,000
New +$1.34M 0.69% 52
2016
Q1 		– Sell
-64,000
Closed -$4.91M – 55
2015
Q4 		$4.91M Buy
+64,000
New +$3.62M 2.53% 14
2014
Q4 		– Sell
-21,500
Closed -$2.08M – 76
2014
Q3 		$2.08M Sell
21,500
-1,500
-7% -$146K 1.6% 27
2014
Q2 		$2.11M Sell
23,000
-12,000
-34% -$914K 1.72% 23
2014
Q1 		$2.45M Buy
35,000
+12,000
+52% +$816K 2.09% 16
2013
Q4 		$1.32M Buy
+23,000
New +$1.21M 1.18% 34

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return